Red Blood Cell Inclusion Bodies

Introduction

Open any hematology atlas and you will see them: small, dark spots, faint blue dots, threadlike loops, or pale rings tucked inside red blood cells. These are inclusion bodies. They look like minor details, but for a clinician or a trainee learning to read a blood smear, they are often the first clue to what is going wrong inside a patient.

This article focuses on the inclusion bodies you are most likely to meet in undergraduate hematology and on the wards. We will cover what each one is made of, how it appears under the microscope, which stains confirm it, and what disorder it points toward. A separate article covers red cell size, shape, and color in detail so we will not repeat that ground here.

An inclusion body is, simply, abnormal material trapped inside a red blood cell that does not belong there. It might be leftover DNA, denatured hemoglobin, iron, ribosomes, mitotic remnants, or an actual parasite. Each has a different cause, and that is what makes them clinically useful.

How to Approach an Inclusion on a Smear

Before diving into each type, it helps to have a workflow. When a smear flags an inclusion, we should think in four steps:

1. Identify the inclusion by its size, color, location in the cell, and number.
2. Confirm with the appropriate stain (Wright-Giemsa for most), Prussian blue for iron-containing inclusions, and a supravital stain (brilliant cresyl blue or new methylene blue) for Heinz and HbH inclusions [2,4].
3. Correlate with the complete blood count (CBC), red cell indices, reticulocyte count, and clinical history (recent splenectomy, drug exposure, ethnicity, suspected lead exposure).
4. Escalate with targeted tests: hemoglobin electrophoresis, G6PD assay, blood lead level, bone marrow examination, or molecular testing such as SF3B1 sequencing [5,6].

Common RBC Inclusion Bodies

Common RBC morphology in terms of size, shape, color, and distribution has been covered in the RBC morphology post. This article, we will be focusing on common RBC inclusion bodies seen in hematological disorders. 

Nucleated Red Blood Cells (Normoblasts)

A nucleated red blood cell is an immature erythrocyte that has not yet ejected its nucleus. Strictly speaking, the nucleus is not a cytoplasmic inclusion but NRBCs are conventionally grouped with inclusions because the dark central nucleus reads like one on a smear [1].

NRBCs should not appear in adult peripheral blood. When they do, it usually means the bone marrow is stressed:

• Severe anemia of any cause, especially hemolytic anemia and thalassemia major.
• Bone marrow infiltration — leukemia, myelofibrosis, metastatic tumor, granulomatous disease.
• Acute blood loss or severe hypoxia.
• Newborns, in whom small numbers of NRBCs are normal in the first days of life.

Modern automated hematology analyzers report NRBC counts directly per 100 white cells. In hospitalized adults, a positive NRBC count is an independent marker of poor prognosis, particularly in ICU settings.

Howell-Jolly Bodies

Howell-Jolly bodies are small, round, dark-purple dots, typically 0.5 to 1 μm across, sitting in the cytoplasm of an otherwise mature red cell. They are pieces of leftover nuclear DNA that should have been pinched off by the spleen as the young red cell passed through it [1,2].

A healthy spleen efficiently removes these remnants. So if they appear in the circulation, the spleen is the prime suspect.

Common causes:

• Asplenia — surgical removal (splenectomy) or congenital absence.
• Functional hyposplenism — sickle cell disease (autosplenectomy), severe celiac disease, amyloidosis [1].
• Severe megaloblastic anemia — much less common, and usually accompanied by macrocytic oval red cells.

A related but more sensitive marker of splenic function is the pitted red cell count, measured by interference microscopy, which detects subtle hyposplenism before Howell-Jolly bodies appear on routine smears [2].

Basophilic Stippling

Basophilic stippling shows up as numerous fine to coarse dark-blue dots scattered evenly through the cytoplasm. The granules are aggregated ribosomal RNA that failed to be broken down during red cell maturation [1,3].

Common causes:

• Lead poisoning — classic association; lead inhibits the enzyme pyrimidine 5'-nucleotidase, blocking RNA degradation [1].
• Congenital pyrimidine 5'-nucleotidase deficiency — a rare hereditary hemolytic anemia that produces identical coarse stippling to lead poisoning [12].
• Thalassemia — disordered hemoglobin synthesis (typically coarse stippling) [1].
• Megaloblastic anemia — vitamin B12 or folate deficiency [1].
• Sideroblastic anemia and myelodysplastic syndromes [1].
• Chronic alcoholism [1].

Note: Fine stippling can occasionally be seen in a wide variety of conditions or as a drying artifact, whereas coarse stippling strongly points to the conditions above [12].

Siderotic Granules (Pappenheimer Bodies)

Pappenheimer bodies are small, dense, blue-black granules clustered toward the edge of the red cell. They contain hemosiderin (a storage form of iron) [2,4].

On a routine Wright stain, they can be confused with basophilic stippling. The deciding test is Prussian blue, which stains iron specifically. A positive Prussian blue confirms Pappenheimer bodies and identifies the cell as a siderocyte.

Common causes:

• Sideroblastic anemia (hereditary or acquired).
• Hyposplenism or post-splenectomy.
• Hemoglobinopathies, including thalassemia.
• Iron overload states such as hereditary hemochromatosis and transfusion-dependent anemias [4].

Heinz Bodies

Heinz bodies are aggregates of denatured hemoglobin pushed up against the inner red cell membrane. They are the footprint of oxidative damage [1,10].

Heinz bodies are not visible on a routine Wright-Giemsa stain. A supravital stain such as brilliant cresyl blue, methyl violet, or crystal violet is required. This makes them easy to miss if the wrong stain is ordered [1,2,9].

Common causes:

• G6PD deficiency — the classic example. Exposure to oxidant drugs (dapsone, primaquine, certain sulfonamides), naphthalene mothballs, or fava beans triggers hemolysis with Heinz bodies [1].
• Unstable hemoglobins (e.g., Hb Köln, Hb Zürich).
• Chemical or drug-induced oxidative injury.

Once Heinz bodies form, the spleen tries to pluck them out, often taking a chunk of membrane with them. The resulting "bite cells" are a useful companion finding on the smear.

H Inclusions in Hb H Disease

HbH inclusions are precipitates of β4 tetramers (Hemoglobin H), formed when α-globin chain production is severely reduced, which is the situation in HbH disease, a severe form of α-thalassemia [10].

Stained with brilliant cresyl blue, the cells take on a distinctive "golf ball" or "raspberry" appearance: many fine, evenly distributed blue dots across the entire cell. This contrasts with Heinz bodies, which usually appear as one or two larger clumps near the membrane.

HbH inclusions overlap mechanistically with Heinz bodies in that both are precipitated globin, but they are reported separately because their cause (α-thalassemia) and treatment implications are distinct. Brilliant cresyl blue staining is a useful screening test; definitive diagnosis now relies on molecular analysis of the α-globin gene cluster [10].

Parasites

Some red cell "inclusions" are not host material at all — they are organisms living inside the cell.

Malaria (Plasmodium species) is the most important worldwide. Early-stage ring forms appear as fine blue rings with a single red chromatin dot. As the parasite matures, it forms trophozoites, schizonts, or gametocytes, each with species-specific features. P. falciparum classically shows multiple ring forms in a single cell and very high parasitemia [1].

Babesia species cause babesiosis, a tick-borne illness. Babesia appears as small, pear-shaped or ring forms, sometimes in a characteristic "Maltese cross" tetrad. They can be confused with P. falciparum on rapid review.

Diagnostic update: thick and thin smear microscopy is still the WHO reference standard for malaria. Rapid diagnostic tests (detecting HRP-2 or pLDH antigens) are routinely paired with smears as the immediate first-line workup. Species-specific PCR is highly sensitive and used globally as a confirmatory test, especially when microscopy is equivocal or to detect mixed infections [1,13].

Ring Sideroblasts

Ring sideroblasts are different from the other entries on this list in one important way: they are not seen on a peripheral blood smear. They are found in the bone marrow.

A ring sideroblast is an immature red cell (erythroblast) with iron-laden mitochondria forming a ring of blue-staining granules around the nucleus on Prussian blue stain.

Under the 2022 WHO Classification of Haematolymphoid Tumours and the International Consensus Classification 2022, the diagnosis of MDS with ring sideroblasts has shifted toward molecular criteria [5,6]. Specifically:

• The new entity MDS-SF3B1 is defined primarily by the presence of an SF3B1 mutation. If this mutation is present, there is no minimum percentage of ring sideroblasts required for the diagnosis [5,6].
• The WHO and ICC guidelines now diverge if the SF3B1 mutation is absent. The 2022 WHO classification completely retires "MDS with ring sideroblasts" as a diagnosis (reclassifying these cases based on blast count, e.g., MDS with low blasts), whereas the ICC retains the category "MDS, not otherwise specified, with ring sideroblasts" for cases with ≥15% ring sideroblasts and wild-type SF3B1 [5,6,11,14].
• For lower-risk MDS with ring sideroblasts that are transfusion-dependent, luspatercept is now an established second-line option following the MEDALIST trial [8].

Common causes of ring sideroblasts:

• Congenital sideroblastic anemias (X-linked, ALAS2 mutations).
• Acquired sideroblastic anemias — myelodysplastic syndromes, especially MDS-SF3B1.
• Reversible causes — vitamin B6 deficiency, copper deficiency (often from zinc excess), chronic alcoholism, certain drugs (isoniazid, chloramphenicol, linezolid).

Cabot Rings

Cabot rings are rare, delicate, threadlike, reddish-violet structures forming a loop or figure-of-eight inside the red cell. They are thought to be remnants of the mitotic spindle or nuclear membrane, although their exact origin remains debated [1,2].

They are visible on routine Wright-Giemsa staining and signal severely disordered red cell production (dyserythropoiesis). Their main associations are:

• Megaloblastic anemia (B12 or folate deficiency, pernicious anemia).
• Lead poisoning.
• Myelodysplastic syndromes.
• Other severe anemias.

Cabot rings should not be confused with stain precipitate or fibrin strands. They lie inside the cell.

Quick Reference: Which Stain Confirms Which Inclusion?

Inclusion Bodies in Clinical Context

An inclusion is a clue, not a diagnosis. The same inclusion can appear in several disorders, and the same disorder may produce more than one inclusion. Interpretation depends on three things working together:

• Clinical presentation — fatigue, jaundice, splenectomy history, travel, drug exposure, occupational lead risk.
• The rest of the CBC — red cell indices (MCV, MCH), reticulocyte response, platelet and white cell findings.
• Targeted follow-up testing — hemoglobin electrophoresis, G6PD assay, lead level, bone marrow biopsy, or molecular tests such as SF3B1 sequencing [5,6,7].

Frequently Asked Questions (FAQs)

What are red blood cell inclusion bodies?

Red blood cell inclusion bodies are abnormal structures inside red blood cells that should not normally be there. They can be leftover bits of DNA, clumps of damaged hemoglobin, iron granules, ribosomes, or even infectious parasites. Each type points to a different underlying disorder, so spotting them on a blood smear is a useful diagnostic clue.

Are Howell-Jolly bodies always a sign of a missing spleen?

Not always, but the spleen is the main consideration. Howell-Jolly bodies are nuclear fragments that a healthy spleen normally filters out. Their presence usually points to asplenia (after splenectomy), congenital absence of the spleen, or functional hyposplenism (as in sickle cell disease). They can occasionally appear in severe megaloblastic anemia, but in that case the picture is dominated by macrocytic, oval red cells rather than the Howell-Jolly bodies themselves.

What is the difference between Heinz bodies and HbH inclusions?

Both are made of abnormal hemoglobin and both need a supravital stain to be seen, but their cause and appearance differ. Heinz bodies are formed when oxidative stress damages hemoglobin, common in G6PD deficiency, certain drug reactions, and unstable hemoglobins. They appear as one or two clumps stuck to the cell membrane. HbH inclusions are precipitates of β4 tetramers caused by missing α-globin chains in HbH disease (a severe form of α-thalassemia). They appear as numerous fine dots scattered across the cell, giving a "golf ball" look.

Which stain do I use to confirm Pappenheimer bodies versus basophilic stippling?

Both inclusions are visible on a routine Wright or Wright-Giemsa smear, but they look similar at low power. The deciding test is Prussian blue. Pappenheimer bodies contain iron (hemosiderin) and stain positive with Prussian blue; basophilic stippling is made of ribosomal RNA and does not stain with Prussian blue. This single stain answers the question.

Do automated hematology analyzers detect inclusion bodies?

Modern analyzers can flag possible inclusions and report nucleated red blood cell counts directly, but they cannot reliably classify the type of inclusion. A flag from the analyzer triggers a manual smear review by a trained morphologist. AI-assisted digital morphology systems are increasingly used to speed up this review, but the final morphologic call still rests with a human expert.

Has the classification of sideroblastic anemia changed recently?

Yes. Under the WHO 2022 and ICC 2022 classifications of myeloid neoplasms, MDS with ring sideroblasts has shifted toward a molecular definition. MDS-SF3B1 is now diagnosed primarily by detecting an SF3B1 mutation, with ring sideroblasts no longer required at the previous ≥15% threshold when the mutation is present [5–7]. This reflects a broader move in hematopathology from morphology-only to molecularly anchored diagnoses.

Glossary of Related Medical Terms

• Anisocytosis — Variation in red blood cell size on a smear.
• Asplenia — Absence of a working spleen, either from surgical removal or congenital absence.
• Basophilic — Stains blue or purple with basic dyes; indicates RNA or nuclear material.
• Dyserythropoiesis — Abnormal or disordered production of red blood cells in the bone marrow.
• Erythropoiesis — The process of making red blood cells, mainly in the bone marrow.
• G6PD deficiency — A genetic enzyme deficiency that makes red cells fragile under oxidative stress.
• Heme — The iron-containing part of hemoglobin that binds oxygen.
• Hemoglobinopathy — Any inherited disorder of hemoglobin structure or production, such as sickle cell disease or thalassemia.
• Hemolytic anemia — Anemia caused by red blood cells breaking down faster than they can be replaced.
• Hemosiderin — A storage form of iron in tissues; stains with Prussian blue.
• Hyposplenism — A spleen that works less effectively than it should, even if anatomically present.
• Inclusion body — Any abnormal material inside a red blood cell that does not normally belong there.
• Mitotic spindle — The protein structure that pulls chromosomes apart during cell division.
• Myelodysplastic syndrome (MDS) — A group of bone marrow cancers in which blood cells fail to mature properly.
• Oxidative stress — Cell damage caused by an imbalance between harmful free radicals and protective antioxidants.
• Peripheral blood smear — A thin film of blood on a glass slide, stained and examined under a microscope.
• Reticulocyte — A young red blood cell still carrying some RNA.
• Romanowsky stain — The family of stains (Wright, Giemsa, Wright-Giemsa) used for routine blood smears.
• SF3B1 — A gene encoding a splicing factor; mutations are strongly linked to MDS with ring sideroblasts.
• Supravital stain — A stain (e.g., brilliant cresyl blue) applied to living cells to reveal structures invisible on routine smears.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Yonder S, Boothe P, Zubair M, et al. Erythrocyte Inclusions. [Updated 2025 Dec 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK594259/
2. Tyrrell, L., Rose, G., Shukri, A., & Kahwash, S. B. (2021). Morphologic changes in red blood cells: An illustrated review of clinically important light microscopic findings. The Malaysian journal of pathology, 43(2), 219–239.
3. Ford J. (2013). Red blood cell morphology. International journal of laboratory hematology, 35(3), 351–357. https://doi.org/10.1111/ijlh.12082
4. Constantino B. T. (2015). Reporting and grading of abnormal red blood cell morphology. International journal of laboratory hematology, 37(1), 1–7. https://doi.org/10.1111/ijlh.12215
5. Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., Chen, W., Chen, X., Chng, W. J., Choi, J. K., Colmenero, I., Coupland, S. E., Cross, N. C. P., De Jong, D., Elghetany, M. T., Takahashi, E., … Hochhaus, A. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 36(7), 1703–1719. https://doi.org/10.1038/s41375-022-01613-1
6. Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H. M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., Bueso-Ramos, C. E., Cortes, J. E., Dal Cin, P., DiNardo, C. D., Dombret, H., Duncavage, E. J., Ebert, B. L., Estey, E. H., Facchetti, F., Foucar, K., … Tefferi, A. (2022). International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200–1228. https://doi.org/10.1182/blood.2022015850
7. Mortuza, S., Chin-Yee, B., James, T. E., Chin-Yee, I. H., Hedley, B. D., Ho, J. M., Saini, L., Lazo-Langner, A., Schenkel, L., Bhai, P., Sadikovic, B., Keow, J., Sangle, N., & Hsia, C. C. (2024). Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review. Current oncology (Toronto, Ont.), 31(4), 1762–1773. https://doi.org/10.3390/curroncol31040134
8. Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Cazzola, M., Ilhan, O., Sekeres, M. A., Falantes, J. F., Arrizabalaga, B., Salvi, F., Giai, V., Vyas, P., Bowen, D., Selleslag, D., DeZern, A. E., Jurcic, J. G., … List, A. F. (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. The New England journal of medicine, 382(2), 140–151. https://doi.org/10.1056/NEJMoa1908892
9. Bain, B. J., Leach, M. (2025). Blood cells: A practical guide (7th ed.). Wiley.
10. Musallam, K. M., Cappellini, M. D., Coates, T. D., Kuo, K. H. M., Al-Samkari, H., Sheth, S., Viprakasit, V., & Taher, A. T. (2024). Αlpha-thalassemia: A practical overview. Blood reviews, 64, 101165. https://doi.org/10.1016/j.blre.2023.101165
11. Vicente, A. I., Luna, I., Ruiz, J. C., Remigia, M. J., Jerez, A., Lluch, R., Llopis, I., Marco, M. J., Benet, C., Alonso, C., Linares, M. D., Serrano, L., Orero, M. T., Ortuño, F. J., & Senent, M. L. (2024). WHO/ICC Classification for Myelodysplastic Neoplasms/Syndromes Performs Better for Subtype Cytomorphological Diagnosis?. Diagnostics (Basel, Switzerland), 14(15), 1631. https://doi.org/10.3390/diagnostics14151631
12. Zanella, A., Bianchi, P., Fermo, E., & Valentini, G. (2006). Hereditary pyrimidine 5'-nucleotidase deficiency: from genetics to clinical manifestations. British journal of haematology, 133(2), 113–123. https://doi.org/10.1111/j.1365-2141.2006.05992.x
13. World Health Organization. (2025). WHO Guidelines for Malaria. Geneva: World Health Organization.
14. Lee, W. H., Lin, C. C., Tsai, X. C., Tien, F. M., Lo, M. Y., Tseng, M. H., Kuo, Y. Y., Yu, S. C., Liu, M. C., Yuan, C. T., Yang, Y. T., Chuang, M. K., Ko, B. S., Tang, J. L., Sun, H. I., Chuang, Y. K., Tien, H. F., Hou, H. A., & Chou, W. C. (2024). Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms. Blood cancer journal, 14(1), 57. https://doi.org/10.1038/s41408-024-01031-9